Drug Profile
Estriol/lactobacillus - Acerus Pharmaceuticals/Medinova
Alternative Names: Estriol-Lactobcillus acidophilus mixt. - Acerus/Medinova; Estriol/lyophilised lactobacilli - Acerus/Medinova; Gynoflor; Ultra-low dose estrogen/lactobacillus - Acerus/MedinovaLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Medinova
- Developer Acerus Pharmaceuticals; Medinova
- Class Estrenes; Hormonal replacements; Probiotics
- Mechanism of Action Estrogen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Atrophic vaginitis; Infections